PYPD
NASDAQ HealthcarePolyPid Ltd. - Ordinary Shares
Biotechnology
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
�� 市场数据
| 价格 | $5.19 |
|---|---|
| 成交量 | 183,837 |
| 市值 | 99.51M |
| 贝塔系数 | 1.400 |
| RSI（14日） | 62.1 |
| 200日均线 | $4.29 |
| 50日均线 | $4.81 |
| 52周最高 | $5.62 |
| 52周最低 | $3.06 |
| Forward P/E | -4.14 |
| Price / Book | 11.33 |
🎯 投资策略评分
PYPD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (69/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PYPD in your text
粘贴任何文章、记录或帖子 — 工具将提取 PYPD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.